Skip to main content

New Drug Approvals 2013 - Pt. VIII - Fluticasone furoate and Vilanterol (Breo ElliptaTM)

ATC Code: R03AK10
Wikipedia: Vilanterol

On May 10th, the FDA approved Vilanterol (Tradename: Breo Ellipta; Research Code: GW-642444M), a long-acting beta2-adrenergic agonist, in combination with the already approved fluticasone furoate, an inhaled corticosteroid, for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is characterised by the occurrence of chronic bronchitis or emphysema, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. Bronchial spasms, a sudden constriction of the muscles in the walls of the bronchioles, occur frequently in COPD.

Vilanterol is a new long-acting beta2 receptor agonist that through the activation of the beta2 adrenergic receptors present in the bronchial smooth muscle, leads to bronchodilation, and consequently eases the symptoms of COPD.

The beta2 adrenergeic receptor (Uniprot: P07550; ChEMBL: CHEMBL210) belongs to the G-protein coupled receptor (GPCR) type 1 family, and binds the endogenous neurotransmitter adrenaline. Since it is coupled to a Gs protein, its activation leads ultimately to an increase in cyclic AMP (cAMP), which cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

>ADRB2_HUMAN Beta-2 adrenergic receptor

There are 11 resolved 3D structures for this protein with vary degrees of resolution (2.40 to 3.50 &#197) and different fusion protocols. For instance, 3ny8, is a fused protein of the human beta2 adrenergeic receptor with Lysozyme Bacteriophage T4, with a resolution of 2.84 &#197 and an inverse agonist bound to it (ICI-118,551, ChEMBL: CHEMBL513389):

The full list of PDBe entries can be found here.

The -terol USAN/INN stem covers bronchodilators structurally related with phenethylamine. Members of these class include for example Salmeterol (ChEMBL: CHEMBL1263), Formoterol (ChEMBL: CHEMBL1256786) and Indacaterol (ChEMBL: CHEMBL1095777), all long-acting beta2-adrenergic agonists also approved for the management of COPD. For a full list of compounds check ChEMBL.

Vilanterol (IUPAC Name: 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Canonical smiles: OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl; ChEMBL: CHEMBL1198857; PubChem: 10184665; ChemSpider: 8360167; Standard InChI Key: DAFYYTQWSAWIGS-DEOSSOPVSA-N) is a synthetic small molecule, with a molecular weight of 486.4 Da, 6 hydrogen bond acceptors, 4 hydrogen bond donors, and has an ALogP of 4.22. The compound is therefore fully compliant with the rule of five.

Breo Ellipta is available as a dry powder inhaler and the recommended daily dose is one inhalation of fluticasone furoate/vilanterol 100/25 mcg. Following inhalation, vilanterol peak plasma concentrations are reached within 10 minutes, and its absolute bioavailability is 27.3%. At steady state, following intravenous administration, the mean volume of distribution of vilanterol (Vd/F) was 165L in healthy subjects. Vilanterol is strongly bound to human plasma proteins (93.3 %).

Vilanterol is primarily metabolized in the liver by CYP3A4. Therefore, concomitant administration of potent CYP3A4 inhibitors should be avoided. Vilanterol metabolites are primarily excreted in urine (70%) and feces (30%). The effective half-life (t1/2) for Vilanterol is approximately 21 hours in patients with COPD.

Breo Ellipta has been issued with a black box warning due to Vilanterol increased risk of asthma-related death, a known risk to all long-acting beta2-adrenergic agonists.

The license holder for Breo ElliptaTM is GlaxoSmithKline, and the full prescribing information can be found here.


Popular posts from this blog

ChEMBL_27 SARS-CoV-2 release

The COVID-19 pandemic has resulted in an unprecedented effort across the global scientific community. Drug discovery groups are contributing in several ways, including the screening of compounds to identify those with potential anti-SARS-CoV-2 activity. When the compounds being assayed are marketed drugs or compounds in clinical development then this may identify potential repurposing opportunities (though there are many other factors to consider including safety and PK/PD considerations; see for example The results from such compound screening can also help inform and drive our understanding of the complex interplay between virus and host at different stages of infection.
Several large-scale drug screening studies have now been described and made available as pre-prints or as peer-reviewed publications. The ChEMBL team has been following these developments with significant interest, and as a contribution t…

RDKit, C++ and Jupyter Notebook

Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible?

Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook!

We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it.

With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below:
docker pull eloyfelix/rdkit_jupyter_clingdocker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_clingopen http://localhost:9999/notebooks/rdkit_cling.ipynb in a browser

FPSim2, a simple Python3 molecular similarity tool

FPSim2 is a new tool for fast similarity search on big compound datasets (>100 million) being developed at ChEMBL. We started developing it as we needed a Python3 library able to run either in memory or out-of-core fast similarity searches on such dataset sizes.

It's written in Python/Cython and features:
A fast population count algorithm (builtin-popcnt-unrolled) from using SIMD instructions.Bounds for sub-linear speed-ups from 10.1021/ci600358fA compressed file format with optimised read speed based in PyTables and BLOSCUse of multiple cores in a single search In memory and on disk search modesSimple and easy to use
Source code is available on github and Conda packages are also available for either mac or linux. To install it type:

conda install rdkit -c rdkitconda install fpsim2 -c efelix
Try it with docker (much better performance than binder):

    docker pull eloyfelix/fpsim2    docker run -p 9999:9999 eloyfelix/fpsim2    open htt…

2019 and ChEMBL – News, jobs and birthdays

Happy New Year from the ChEMBL Group to all our users and collaborators. 
Firstly, do you want a new challenge in 2019?  If so, we have a position for a bioinformatician in the ChEMBL Team to develop pipelines for identifying links between therapeutic targets, drugs and diseases.  You will be based in the ChEMBL team but also work in collaboration with the exciting Open Targets initiative.  More details can be found here(closing date 24thJanuary). 
In case you missed it, we published a paper at the end of last on the latest developments of the ChEMBL database “ChEMBL: towards direct deposition of bioassay data”. You can read it here.  Highlights include bioactivity data from patents, human pharmacokinetic data from prescribing information, deposited data from neglected disease screening and data from the IMI funded K4DD project.  We have also added a lot of new annotations on the therapeutic targets and indications for clinical candidates and marketed drugs to ChEMBL.  Importantly we ha…

ChEMBL 25 and new web interface released

We are pleased to announce the release of ChEMBL 25 and our new web interface. This version of the database, prepared on 10/12/2018 contains:

2,335,417 compound records1,879,206 compounds (of which 1,870,461 have mol files)15,504,603 activities1,125,387 assays12,482 targets72,271 documents

Data can be downloaded from the ChEMBL ftp site:

Please see ChEMBL_25 release notes for full details of all changes in this release:


# Deposited Data Sets:

Kuster Lab Chemical Proteomics Drug Profiling (src_id = 48, Document ChEMBL_ID = CHEMBL3991601):
Data have been included from the publication: The target landscape of clinical kinase drugs. Klaeger S, Heinzlmeir S and Wilhelm M et al (2017), Science, 358-6367 (

# In Vivo Assay Classification:

A classification…